From gorilla encounters in Uganda to a reimagined Okavango retreat, Abercrombie & Kent elevates its African journeys with two spectacular lodge transformations.
5 min
Abercrombie & Kent has strengthened its position as the world’s leading experiential travel company with two newly transformed lodges in Africa, signalling a new era of tailormade luxury for guests seeking deeply personal, once-in-a-lifetime journeys on the continent that shaped the brand more than 60 years ago.
For A&K, Africa is not just another destination; it is the birthplace of the company and the foundation of its pioneering approach to responsible luxury travel.
Tailormade journeys allow guests to explore this vast continent entirely on their own terms, supported by a global network of destination experts, specialist guides, and on-the-ground “guardian angels” available around the clock.
Every tailormade itinerary is a fully customised experience, interweaving iconic highlights with hidden wonders. Whether guests dream of tracking wildlife on remote plains, discovering ancient cultures, or reconnecting with family in one of Africa’s most inspiring landscapes, each journey is designed to be as unique as the traveller themselves.
Abercrombie & Kent’s African portfolio has entered a new chapter with the reveal of two extensively rebuilt Sanctuary lodges in Uganda and Botswana, each designed to elevate the experience of Tailormade travel, the luxury company’s signature approach to deeply personal, fully customised journeys.
For more than 60 years, A&K has drawn on its roots in East Africa to craft exceptional, high-touch adventures for travellers seeking privacy, immersion and meaning.
With the reopening of Gorilla Forest Lodge in Uganda and Baines’ Lodge in Botswana’s Okavango Delta, the brand is doubling down on the blend of design, wildlife access and sustainability that has long set it apart.
Tucked inside one of the world’s most biologically rich regions, Gorilla Forest Lodge, an A&K Sanctuary, has long had a singular claim: it is the only luxury lodge located within the actual boundaries of Bwindi Impenetrable National Park.
Already extraordinary in location, the lodge has now undergone a complete transformation — and the result is a deeply refined, fully immersive sanctuary designed with both sensitivity and ambition.
The rebuild significantly expands each of the ten guest suites, creating generous private sanctuaries suspended in the rainforest canopy. Interiors draw directly from local craft traditions — banana-fibre ceilings, handwoven textiles, reclaimed woodwork and artisanal detailing made in nearby communities. The effect is layered, tactile and unmistakably Ugandan.
Bathrooms have been reimagined as spa-like retreats, with freestanding bathtubs positioned for forest views and rain showers opening to private decks. Each suite now includes its own lounge, an oversized bed, and an elevated deck where guests often spot the region’s famed mountain gorillas at dawn.
The lodge’s redesign continues A&K’s decades-long commitment to Uganda’s local communities. Every stay contributes to A&K Philanthropy projects, including education initiatives and healthcare access for villages bordering the park.
Geoffrey Kent’s deep history in Uganda, stretching back more than 40 years, is woven into the property’s ethos. Guests can participate in conservation-oriented activities, guided by expert trackers who work directly with the Uganda Wildlife Authority.
Gorilla trekking remains one of the most extraordinary wildlife experiences on the planet. Being based inside the park means trekking groups can depart directly from the lodge, often reaching gorilla families in shorter times than guests staying outside the gates.
The result is an experience that feels both exclusive and unhurried, exactly what A&K’s Tailormade travellers value.
Botswana’s Okavango Delta is one of Africa’s most iconic landscapes — a shifting world of floodplains, lagoons and wildlife-rich islands. Within this UNESCO World Heritage Site, Baines’ Lodge, an A&K Sanctuary, has emerged from a top-to-bottom rebuild that elevates it into one of the most intimate and design-driven lodges in the Delta.
Set on the banks of the Boro River, the new Baines’ Lodge is constructed on stilts, lifting the six suites high above the floodplains. The architecture embraces an “African pavilion gallery” concept: column-lined walkways, soaring ceilings and open-sided lounges that dissolve the barrier between interior and wilderness.
The colour palette draws from the Delta itself — muted greens, reeds, sun-washed timber, handwoven ceilings and raw natural textures that give the lodge a sculptural quietness.
Every suite has been reimagined with:
• Deep soak tubs with uninterrupted water views
• Private decks and outdoor seating for birdwatching and stargazing
• Contemporary African art and artisanal pieces
• Expansive indoor-outdoor bathrooms
• King beds with mosquito-net canopies
• Soft, indirect lighting that mirrors the Delta’s shifting tones
Despite its refined interiors, the lodge remains deeply committed to environmental sensitivity. Lunawood, a lightweight timber material, forms much of the structure, ensuring minimal environmental impact and allowing the lodge to be removed without damaging the landscape, which is an unusually progressive approach for a luxury property.
Because the lodge is located on a permanent channel of the Delta, game viewing is exceptional year-round. Guests can explore by:
• Mokoro (traditional dugout canoe)
• Motorboat
• Guided walking safaris
• 4×4 game drives
• Private river cruises
• Sundowner excursions along the floodplains
The area is known for elephant herds, wild dogs, lions, leopards, hippos and rare birdlife, all often visible directly from the lodge’s deck.
While many safari operators offer luxury, A&K’s Tailormade approach is built around something rarer: absolute personalisation.
Guests receive access to:
• Private guides and handpicked specialists
• Seamless logistics across remote areas
• Behind-the-scenes experiences not open to the public
• 24/7 on-the-ground support
• Carefully choreographed transfers between lodges, parks and cities
• Exclusive conservation and community activities
The reopening of Gorilla Forest Lodge and Baines’ Lodge marks a significant investment in Africa by Abercrombie & Kent, reinforcing its mission to offer world-leading luxury experiences that honour place, elevate culture and maintain a light environmental footprint.
Both properties are now open, with bookings available as part of fully Tailormade itineraries crafted exclusively by A&K’s global network of experts.
Following the successful launch of its Palais Collection, MAISON de SABRÉ has unveiled a new modular handbag system offering more than 720 styling combinations.
Automobili Lamborghini and Babolat have expanded their collaboration with five new colourways for the ultra-exclusive BL.001 racket, limited to just 50 pieces worldwide.
As millions flock to GLP-1s, doctors warn the drugs can cause rapid and significant muscle loss.
5 min
Chanel Robinson achieved exactly what the gold rush of blockbuster weight-loss drugs promised: She lost nearly 100 pounds, lowered her cholesterol to normal levels and reined in her polycystic ovary syndrome.
Yet, nearly three years into her journey on Mounjaro, the 30-year-old from Atlanta, Ga., is discovering the hidden costs of the slimmed-down life.
Robinson experiences muscle fatigue daily, feeling physically weak, frail and often cold. Robinson said she experiences bursts of sluggishness sporadically during the day, and has trouble with basic tasks like opening a jar. “It shouldn’t be this difficult,” she said.
GLP-1 drugs like Ozempic, Mounjaro and Zepbound have been a success for public health and the pharmaceutical companies that make them. Obesity rates are falling, the volume of food consumed in America is declining and retailers report a slump in sales of plus-size apparel. It has improved health and happiness for millions of people.
But for at least some of the 13 million Americans taking them, losing muscle along with fat is an unexpected downside that isn’t broadly discussed or immediately apparent.
The drugs can cause rapid and significant loss of lean muscle mass, up to 10%, comparable to a decade or more of aging, according to an analysis published by the American Diabetes Association.
The loss of lean tissue is similar to weight loss from dieting, but the magnitude over a short period can lead to frailty, instability and lack of coordination, doctors and researchers say. Another concern is that losing muscle could slow down patients’ metabolism, leading to weight regain.
“We are curing obesity by encouraging frailty,” said Daniel Green, principal research fellow at the University of Western Australia, who contributed to the analysis. Many taking weight-loss medications initially lose fat and feel great, but quickly start to feel weak and lethargic, he said.
Green’s research showed that the rate of muscle loss could be slowed significantly by regular strength workouts. “It should say ‘must be taken with resistance training’ on the box,” he said.
Drugmakers say weight-loss drugs should be taken only on the advice of a physician and as part of a long-term plan that includes diet and exercise.
A spokesperson for Eli Lilly, maker of Zepbound, said Food and Drug Administration guidelines say it should be used “with increased physical activity.” The spokesperson added: “Sustainable weight loss is about more than a number on a scale.”
Both Eli Lilly and Novo Nordisk said clinical trials showed users did lose some lean muscle tissue, though at far lower rates than fat. Liz Skrbkova, a spokeswoman for Novo Nordisk, said that trials for its drug Wegovy showed changes in muscle mass didn’t “significantly differ” from patients who took a placebo. Eli Lilly said users lost three times more fat weight than lean tissue.
Rayna Kingston, 30, from Denver, said her injections of Zepbound left her feeling so tired the following day that she struggled to complete anything other than basic tasks. She said she shifted her dose to a Sunday because Mondays were her least busy day. Her partner would bring her meals in bed because she felt so weak.
She stopped exercising, and said her doctor didn’t give her any guidance on strength training or muscle maintenance. “I was relying on Reddit forums to understand what was happening to my body,” she said. She got so frustrated with the fatigue she came off the medication just under two months later.
Experts say that losing muscle at such a rate can be especially dangerous for those over 50 or with osteoporosis or limited mobility as it could lead to an increased risk of injury. “Loss of muscle mass is detrimental to moving around and quality of life, but it is also not safe,” said Katsu Funai, associate professor at the University of Utah.
Elderly Americans are set to be able to get GLP-1s from Medicare from July.
There is also pushback from doctors and regulators against using weight-loss drugs as a “quick fix” to lose a bit of weight.
People who take GLP-1s regain weight four times faster than those who lose weight through lifestyle interventions, and weight regained is often mostly fat, according to a recent analysis published in the British Medical Journal. There currently are few, if any, guidelines or studies on de-prescribing the drugs, researchers say.
The nurse practitioner who prescribed Robinson the medication didn’t warn her that resistance training is essential to maintaining muscle mass, Robinson said. She said she regrets not exercising and now does Pilates once a week.
In the haste to disrupt the obesity epidemic, weight loss has been treated as the singular, undisputed metric of success, which experts say is problematic.
“People worship body weight as an outcome measure because it’s simple, quick and inexpensive,” said Green. “But what matters is fat and muscle mass, which is more expensive to measure as it requires an MRI.”
Grace Parkin, 34, a property manager from Sheffield, England, has lost 125 pounds after she started taking Mounjaro in 2024. “I don’t care about my muscle mass as long as I’m a healthy weight,” she said.
The doctor who prescribed the drug didn’t tell her to exercise, though the pharmacy that sold the medication gave her information on exercise and protein intake, she said.
She didn’t exercise and said she soon felt side effects: a “deathly cold, from the inside” likely because of the drug. Still, she vowed to keep going, saying the weight loss was worth it.
In response to some of the side effects, drug companies are hoping to develop weight-loss treatments aimed at preserving or even building lean muscle mass.
German drugmaker Boehringer Ingelheim recently said it had promising results from one such drug. Eli Lilly last September halted a trial of a similar drug.
While weight-loss medications are designed as lifelong treatments for chronic diseases, namely obesity and Type 2 diabetes, they are increasingly marketed as lifestyle fixes.
Tennis superstar Serena Williams, who used GLP-1s to slim down after having children, was featured in this year’s Super Bowl commercial promoting telehealth company Ro’s weight-loss medication.
Serena Williams poses for an ad campaign for a weight-loss drug. Ro/Handout/Reuters
Women may be particularly vulnerable to the drugs’s side effects, which can also include nausea, diarrhea, migraines and rarer cases of pancreatitis.
A study last year from a university hospital in Turin, Italy, showed that women are more prone to adverse reactions to weight-loss drugs than men, including muscle loss.
Green, the researcher, said the issue is of particular concern to those taking GLP-1s recreationally and who don’t have much muscle mass to begin with. Others say a lack of oversight is compounding the issue.
“Patients are self-reporting, and telehealth companies don’t have the patient in front of them to conduct a proper medical assessment,” said Rupal Mathur, an internist in Houston whose practice specializes in weight loss.
She said medical spas are prescribing off-label drugs that don’t meet the criteria set out by the FDA that justify a prescription.
The number of people taking weight-loss drugs who are not living with obesity or Type 2 diabetes is difficult to track since it is unregulated.
However, an analysis by the FDA from 2023 found that more than half of new Ozempic and Mounjaro users didn’t have Type 2 diabetes.
Scientists are calling for more clinical trials to pin down the full effects of weight-loss drugs on muscle loss in different demographics.
“The only studies that have been done have looked at people living with obesity or Type 2 diabetes,” said Green. “That makes it all the more concerning for those using weight-loss drugs in an ad hoc or unregistered way.”
